SRR8943018
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.410
- MTORC1_SIGNALING+0.390
- OXIDATIVE_PHOSPHORYLATION+0.380
- ANGIOGENESIS+0.360
- ADIPOGENESIS+0.350
- HYPOXIA+0.350
- HEDGEHOG_SIGNALING+0.330
- GLYCOLYSIS+0.310
- NOTCH_SIGNALING+0.310
- FATTY_ACID_METABOLISM+0.290
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.380
- G2M_CHECKPOINT-0.260
- INTERFERON_GAMMA_RESPONSE-0.250
- E2F_TARGETS-0.240
- MITOTIC_SPINDLE-0.200
- IL6_JAK_STAT3_SIGNALING-0.160
- PANCREAS_BETA_CELLS-0.160
- PI3K_AKT_MTOR_SIGNALING-0.120
- ESTROGEN_RESPONSE_EARLY-0.060
- APICAL_SURFACE-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BSR_06_0059_A2_S99 | — | F | 0.782 |
| 2 | c119f5ef.864c.434b.b515.57c27c7ae949 | — | cohortA1 | 0.775 |
| 3 | 20060030.TNBC | — | F | 0.769 |
| 4 | MBCProject_0209_T1_RNA | — | C | 0.762 |
| 5 | R260 | — | — | 0.759 |
| 6 | TCGA-LL-A740-01A-21R-A32P-07 | — | F | 0.743 |
| 7 | GSM5359444 | — | — | 0.741 |
| 8 | TCGA-CR-5247-01A-01R-2016-07 | — | — | 0.741 |
| 9 | d25af392-21ad-4aa6-8669-34656bf71af5 | — | — | 0.729 |
| 10 | TCGA-A2-A04W-01A-31R-A115-07 | — | C | 0.728 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.390 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.380 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.360 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.350 | Inavolisib | — uncovered |
| HYPOXIA | 0.350 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.310 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.310 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.230 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |